Commonwealth Equity Services’s NeuroSense Therapeutics NRSN Stock Holding History

Commonwealth Equity Services’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.4K	Hold	1,139	–	–	﹤0.01%	4378
2026 Q1	$17.2K	Hold	1,139	–	–	﹤0.01%	4262
2025 Q4	$17.5K	Buy	1,139 +85	+8%	+$1.79K	﹤0.01%	4248
2025 Q3	$26K	Hold	1,054	–	–	﹤0.01%	4197
2025 Q2	$40K	Buy	1,054 +191	+22%	+$5.54K	﹤0.01%	4180
2025 Q1	$16K	Buy	863 +50	+6%	+$1.11K	﹤0.01%	4134
2024 Q4	$20K	Buy	813 +182	+29%	+$4.19K	﹤0.01%	4041
2024 Q3	$16K	Buy	+631	New	+$12K	﹤0.01%	4012

Other funds holding NRSN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Commonwealth Equity Services's NRSN Position: Q2 2026 in Review

Commonwealth Equity Services held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 1,139 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4378.

Commonwealth Equity Services first reported a position in NRSN in Q3 2024 and has held it in 8 quarters since. The position peaked at $40K in Q2 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

Commonwealth Equity Services held 1,139 shares of NeuroSense Therapeutics worth $16.4K as of Q2 2026.
Commonwealth Equity Services left its NeuroSense Therapeutics share count unchanged in Q2 2026.
NeuroSense Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4378 holding.
Commonwealth Equity Services first reported a position in NeuroSense Therapeutics in Q3 2024 and has held it in 8 quarters since.
Commonwealth Equity Services's NeuroSense Therapeutics position peaked at $40K in Q2 2025.
12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.